Stem definition | Drug id | CAS RN |
---|---|---|
steroids, progestogens | 1667 | 595-33-5 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
0.16 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 60 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 23.22 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 18, 1971 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 109.50 | 20.36 | 147 | 5170 | 341279 | 55945471 |
Decreased appetite | 107.20 | 20.36 | 117 | 5200 | 219114 | 56067636 |
Malignant neoplasm progression | 70.13 | 20.36 | 57 | 5260 | 73530 | 56213220 |
Neutropenia | 64.57 | 20.36 | 77 | 5240 | 158090 | 56128660 |
Disease progression | 59.89 | 20.36 | 61 | 5256 | 105112 | 56181638 |
Deep vein thrombosis | 53.85 | 20.36 | 50 | 5267 | 76927 | 56209823 |
Metastases to liver | 52.78 | 20.36 | 30 | 5287 | 21556 | 56265194 |
Dehydration | 50.04 | 20.36 | 68 | 5249 | 158757 | 56127993 |
Asthenia | 41.07 | 20.36 | 96 | 5221 | 342877 | 55943873 |
Breast cancer metastatic | 39.16 | 20.36 | 22 | 5295 | 15447 | 56271303 |
Metastases to bone | 36.94 | 20.36 | 23 | 5294 | 19485 | 56267265 |
Diarrhoea | 33.00 | 20.36 | 133 | 5184 | 638374 | 55648376 |
Oestrogen receptor assay positive | 28.41 | 20.36 | 7 | 5310 | 467 | 56286283 |
Meningioma | 27.44 | 20.36 | 11 | 5306 | 3643 | 56283107 |
Rheumatoid arthritis | 25.78 | 20.36 | 3 | 5314 | 382601 | 55904149 |
Papillary thyroid cancer | 25.44 | 20.36 | 9 | 5308 | 2115 | 56284635 |
Breast cancer | 23.62 | 20.36 | 26 | 5291 | 48807 | 56237943 |
Abdominal pain | 23.17 | 20.36 | 65 | 5252 | 258740 | 56028010 |
Weight decreased | 23.08 | 20.36 | 62 | 5255 | 240652 | 56046098 |
Hypoaesthesia oral | 22.97 | 20.36 | 14 | 5303 | 11417 | 56275333 |
Thoracic vertebral fracture | 22.53 | 20.36 | 10 | 5307 | 4253 | 56282497 |
Dysgeusia | 21.92 | 20.36 | 23 | 5294 | 40892 | 56245858 |
Gastritis | 21.31 | 20.36 | 21 | 5296 | 34681 | 56252069 |
Pulmonary embolism | 21.16 | 20.36 | 37 | 5280 | 107087 | 56179663 |
Anaemia | 20.89 | 20.36 | 64 | 5253 | 267447 | 56019303 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Decreased appetite | 80.26 | 19.68 | 122 | 6056 | 153095 | 31538071 |
Death | 76.61 | 19.68 | 196 | 5982 | 360373 | 31330793 |
Malignant neoplasm progression | 76.01 | 19.68 | 85 | 6093 | 78913 | 31612253 |
Asthenia | 66.05 | 19.68 | 139 | 6039 | 224616 | 31466550 |
Dehydration | 63.92 | 19.68 | 96 | 6082 | 119015 | 31572151 |
Adrenal insufficiency | 60.38 | 19.68 | 35 | 6143 | 12624 | 31678542 |
Respiratory tract infection bacterial | 56.89 | 19.68 | 18 | 6160 | 1448 | 31689718 |
Pneumonia | 52.11 | 19.68 | 163 | 6015 | 335149 | 31356017 |
Respiratory tract infection viral | 51.28 | 19.68 | 18 | 6160 | 1996 | 31689170 |
Fatigue | 44.03 | 19.68 | 154 | 6024 | 335052 | 31356114 |
Disease progression | 41.62 | 19.68 | 68 | 6110 | 90396 | 31600770 |
Pulmonary embolism | 39.78 | 19.68 | 63 | 6115 | 81583 | 31609583 |
Anaemia | 30.45 | 19.68 | 101 | 6077 | 213421 | 31477745 |
Diarrhoea | 28.80 | 19.68 | 140 | 6038 | 352269 | 31338897 |
Respiratory tract infection | 24.27 | 19.68 | 23 | 6155 | 17538 | 31673628 |
Dysphagia | 23.37 | 19.68 | 41 | 6137 | 57635 | 31633531 |
Weight decreased | 22.17 | 19.68 | 75 | 6103 | 159877 | 31531289 |
Drug ineffective | 21.98 | 19.68 | 27 | 6151 | 395546 | 31295620 |
Plasma cell myeloma | 20.12 | 19.68 | 38 | 6140 | 56493 | 31634673 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Decreased appetite | 128.36 | 18.85 | 170 | 8371 | 304610 | 70615293 |
Death | 124.91 | 18.85 | 221 | 8320 | 509840 | 70410063 |
Dehydration | 99.49 | 18.85 | 129 | 8412 | 226013 | 70693890 |
Adrenal insufficiency | 76.80 | 18.85 | 44 | 8497 | 25151 | 70894752 |
Asthenia | 70.66 | 18.85 | 164 | 8377 | 457502 | 70462401 |
Malignant neoplasm progression | 68.97 | 18.85 | 79 | 8462 | 121660 | 70798243 |
Respiratory tract infection bacterial | 62.42 | 18.85 | 18 | 8523 | 1719 | 70918184 |
Pulmonary embolism | 59.40 | 18.85 | 83 | 8458 | 155784 | 70764119 |
Disease progression | 59.07 | 18.85 | 83 | 8458 | 156589 | 70763314 |
Pneumonia | 57.93 | 18.85 | 180 | 8361 | 596052 | 70323851 |
Respiratory tract infection viral | 49.81 | 18.85 | 18 | 8523 | 3523 | 70916380 |
Anaemia | 43.99 | 18.85 | 127 | 8414 | 403296 | 70516607 |
Diarrhoea | 40.08 | 18.85 | 193 | 8348 | 783148 | 70136755 |
Neutropenia | 38.27 | 18.85 | 91 | 8450 | 257065 | 70662838 |
Plasma cell myeloma | 35.63 | 18.85 | 44 | 8497 | 73157 | 70846746 |
Deep vein thrombosis | 33.45 | 18.85 | 53 | 8488 | 110989 | 70808914 |
Fatigue | 31.16 | 18.85 | 187 | 8354 | 824132 | 70095771 |
Drug ineffective | 28.85 | 18.85 | 43 | 8498 | 939709 | 69980194 |
Platelet count decreased | 26.41 | 18.85 | 63 | 8478 | 178159 | 70741744 |
Failure to thrive | 25.43 | 18.85 | 16 | 8525 | 10813 | 70909090 |
Constipation | 25.09 | 18.85 | 77 | 8464 | 252361 | 70667542 |
Androgen deficiency | 24.82 | 18.85 | 5 | 8536 | 102 | 70919801 |
Rheumatoid arthritis | 24.82 | 18.85 | 3 | 8538 | 291802 | 70628101 |
Mental status changes | 24.59 | 18.85 | 34 | 8507 | 63067 | 70856836 |
Pleural effusion | 24.20 | 18.85 | 51 | 8490 | 132813 | 70787090 |
Meningioma | 23.85 | 18.85 | 11 | 8530 | 4007 | 70915896 |
Thrombocytopenia | 23.82 | 18.85 | 73 | 8468 | 239037 | 70680866 |
Blood testosterone decreased | 22.56 | 18.85 | 9 | 8532 | 2304 | 70917599 |
Cachexia | 21.69 | 18.85 | 14 | 8527 | 9886 | 70910017 |
Respiratory tract infection | 21.45 | 18.85 | 26 | 8515 | 42372 | 70877531 |
Secondary adrenocortical insufficiency | 21.39 | 18.85 | 9 | 8532 | 2638 | 70917265 |
Hypophagia | 20.24 | 18.85 | 25 | 8516 | 41545 | 70878358 |
None
Source | Code | Description |
---|---|---|
ATC | G03AA04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations |
ATC | G03AB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations |
ATC | G03AC05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens |
ATC | G03DB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnadien derivatives |
ATC | G03FA08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations |
ATC | G03FB04 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations |
ATC | L02AB01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Progestogens |
FDA CS | M0447349 | Progesterone Congeners |
FDA EPC | N0000175602 | Progestin |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D003270 | Contraceptive Agents |
MeSH PA | D003271 | Contraceptive Agents, Female |
MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
MeSH PA | D003278 | Contraceptives, Oral, Hormonal |
MeSH PA | D003280 | Contraceptives, Oral, Synthetic |
MeSH PA | D012102 | Reproductive Control Agents |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:49323 | contraceptive drugs |
CHEBI has role | CHEBI:49326 | synthetic oral contraceptives |
CHEBI has role | CHEBI:50779 | appetite enhancing drug |
CHEBI has role | CHEBI:59826 | progestins |
MeSH PA | D019167 | Appetite Stimulants |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Endometrial carcinoma | indication | 254878006 | DOID:2871 |
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Nutritional deficiency associated with AIDS | indication | 420691000 | |
Cachexia due to HIV | indication | ||
Anorexia from HIV | indication | ||
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Chronic heart failure | contraindication | 48447003 | |
Male hypogonadism | contraindication | 48723006 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Species | Use | Relation |
---|---|---|
Dogs | Alleviation of false pregnancy | Indication |
Dogs | Postponement of estrus | Indication |
Product | Applicant | Ingredients |
---|---|---|
Ovaban Tablets 20 mg, Ovaban Tablets 5 mg | Intervet Inc. | 1 |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 7101576 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9040088 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9101540 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9101549 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
125MG/ML | MEGACE ES | ENDO PHARMS INC | N021778 | July 5, 2005 | RX | SUSPENSION | ORAL | 9107827 | April 22, 2024 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Progesterone receptor | Nuclear hormone receptor | AGONIST | DRUGBANK | CHEMBL | |||||
Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 8.06 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | Ki | 7.70 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 8.84 | DRUG MATRIX |
ID | Source |
---|---|
4022205 | VUID |
N0000020211 | NUI |
D00952 | KEGG_DRUG |
4018133 | VANDF |
4022205 | VANDF |
C0065879 | UMLSCUI |
CHEBI:6723 | CHEBI |
CHEBI:6722 | CHEBI |
CHEMBL1201139 | ChEMBL_ID |
DB00351 | DRUGBANK_ID |
D019290 | MESH_DESCRIPTOR_UI |
11683 | PUBCHEM_CID |
9128 | IUPHAR_LIGAND_ID |
TJ2M0FR8ES | UNII |
29451 | RXNORM |
1784 | MMSL |
5036 | MMSL |
d01348 | MMSL |
002667 | NDDF |
004823 | NDDF |
126091007 | SNOMEDCT_US |
126092000 | SNOMEDCT_US |
38578004 | SNOMEDCT_US |
C0025175 | UMLSCUI |
1529 | INN_ID |
3562-63-8 | SECONDARY_CAS_RN |
D008535 | MESH_DESCRIPTOR_UI |
19090 | PUBCHEM_CID |
EA6LD1M70M | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0887 | SUSPENSION | 625 mg | ORAL | ANDA | 30 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0945 | SUSPENSION | 400 mg | ORAL | ANDA | 21 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4776 | SUSPENSION | 40 mg | ORAL | ANDA | 24 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-4776 | SUSPENSION | 40 mg | ORAL | ANDA | 24 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0606 | TABLET | 20 mg | ORAL | ANDA | 20 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0607 | TABLET | 40 mg | ORAL | ANDA | 20 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-3571 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7072 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7236 | TABLET | 40 mg | ORAL | ANDA | 17 sections |
Megace ES | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-254 | SUSPENSION | 125 mg | ORAL | NDA | 11 sections |
MEGESTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-898 | SUSPENSION | 40 mg | ORAL | ANDA | 4 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0060 | SUSPENSION | 40 mg | ORAL | ANDA | 12 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0907 | SUSPENSION | 40 mg | ORAL | ANDA | 20 sections |
Megace ES | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0949 | SUSPENSION | 125 mg | ORAL | NDA | 25 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-041 | SUSPENSION | 125 mg | ORAL | ANDA | 27 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33358-903 | SUSPENSION | 40 mg | ORAL | ANDA | 10 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-230 | SUSPENSION | 125 mg | ORAL | NDA AUTHORIZED GENERIC | 26 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-230 | SUSPENSION | 125 mg | ORAL | NDA AUTHORIZED GENERIC | 26 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-289 | TABLET | 20 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-289 | TABLET | 20 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-290 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-290 | TABLET | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-907 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-907 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-907 | SUSPENSION | 40 mg | ORAL | ANDA | 22 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-859 | SUSPENSION | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-859 | SUSPENSION | 40 mg | ORAL | ANDA | 19 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-859 | SUSPENSION | 40 mg | ORAL | ANDA | 19 sections |
Megestrol acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-313 | SUSPENSION | 125 mg | ORAL | ANDA | 28 sections |
Megestrol Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0614 | TABLET | 40 mg | ORAL | ANDA | 18 sections |